Promising POTS drug study halted early – what we know
NCT ID NCT05918978
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This study looked at the long-term safety of a drug called efgartigimod for adults with post-COVID POTS, a condition that causes rapid heart rate and dizziness when standing. It was an open-label extension, meaning everyone knew they were getting the drug. The study was terminated early, so results are limited. The main goal was to track side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-COVID POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Apex Trials Group
Fort Worth, Texas, 76104, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
Metrodora Institute
West Valley City, Utah, 84119, United States
-
North Shore University HealthSystem
Glenview, Illinois, 60026, United States
-
Pioneer Clinical Research
Rosharon, Texas, 77583, United States
-
Standford Movement Disorder Center
Palo Alto, California, 94304, United States
-
UC Sand Diego Sulpizio Cardiovascular Center
La Jolla, California, 92037, United States
-
University Hospitals, Neurology Clinical Trials
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.